Bercedis Peterson

Selected Peer-reviewed Publications from over 120.

1. Peterson, BL, Harrell, FE. Partial proportional odds model for ordinal response variables. Journal of
the Royal Statistical Society C 39:205-21, 1990. PMID:23017706
2.Peterson, BL, George, SL. Sample size requirements and length of study for testing interaction in a
2xk factorial design when time-to-failure is the outcome. Controlled Clinical Trials 14:511-211,1993.
PMID:8119066
3. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson
RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic
lymphotcytic leukemia. New England Journal of Medicine 343:1751-1759, 2000. PMID:11114313
4. Potthoff RF, Peterson BL, George SL. Detecting treatment-by-center interaction in multi-center
clinical trials. Statistics in Medicine 20:193-213, 2001. PMID:11169597
5. Silverman LR, Demakos EP, Peterson BL, plus 11 others. A randomized controlled trial of azacitidine
in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. Journal
of Clinical Oncology 20:2429-2440, 2002. PMID:12011120
6. Sartor CI, Peterson BL, Woolf S, FitzGerald TJ, Laurie F, Turrisi AJ, Bogart J, Henderson IC, Norton
L. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node
positive breast cancer: CALGB 9344. Journal of Clinical Oncology 23:30-40, 2005. PMID:15545661
7.Scales C, Norris R, Keitz S, Peterson BL, Preminger G, Vieweg G, Dahm P. A Critical Assessment of
the Quality of Reporting of Randomized, Controlled Trials in the Urology Literature. The Journal of
Urology 177:1090-1095, 2006. PMID:17296417
8. Demark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D, Snyder DC, Sloane R, Peterson BL, Macri
JA, Rock CL, McBride CM, Kraus WE. Main Outcomes of the FRESH START Trial: A SequentiallyTailored, Diet and Exercise, Mailed Print Intervention Among Breast and Prostate Cancer Survivors.
Journal of Clinical Oncology 26: 2709-2718, 2007. PMID:17602076
9. Gollob JA, Rathmell W., Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L,
Peterson BL, Wright JJ. Phase II Trial of Sorafenib Plus Interferon Alpha-2b as First- or Second-Line
Therapy in Patients with Metastatic Renal Cell Cancer. Journal Clinical Oncology 28:3288-3295, 2007
PMID:17664476
10. Swamy GK, Roelands JJ, Peterson BL, Lyna P, Brouwer RJ, Fish LJ, Oncken CA, Pletsch PK,
Myers ER, Pollak KI. Predictors of adverse events among pregnant smokers exposed in a nicotine
replacement therapy trial. American Journal of Obstetrics and Gynecology 201(4):354.e1-7, 2009.
PMCID: PMC2755600
11. Morey MC, Snyder DC, Sloane R, Cohen HJ, Peterson B, Hartman TJ, Miller P, Mitchell D, and
Demark- Wahnefried D. Effects of Home-Based Diet and Exercise on Functional Outcomes Among

Older, Overweight Long-Term Cancer Survivors: The RENEW: Randomized Clinical Trial. Journal of
the American Medical Association 301:1883-1891, 2009. PMCID: PMC2752421
13. Beasley GM, Riboh JC, Augustine CK, Zager JS, Hochwald SN, Grobmeyer SR, Peterson BL,
Royal R, Ross MI, Tyler DS. A Prospective Multi-Center Phase II Trial of Systemic ADH-1 in
Combination with Melphalan via Isolated Limb Infusion (M-ILI) in Patients with Advanced Extremity
Melanoma. Journal of Clinical Oncology 29(9):1210-5, 2011. PMID:21343562
14. Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA,
Byrd JC. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and
progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
Journal of Clinical Oncology 29(10):1349-55, 2011. PMCID:PMC3084002
15. Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E,
Welch RA, Bacus S, Blackwell KL. Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer
Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing. Clinical
Cancer Research 17(18):6061-70, 2011. PMCID: PMC3116034
16. Secord A, Havilresky L, Myers E. Cost-effectiveness of homologous recombination defect testing to
target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. International Journal of
Gynecological Cancer , 2013 (in press)